Martínez Bosch, NeusVilariño, NoeliaAlameda, FrancescMojal, SergiArumí Uria, MontserratCarrato, CristinaAldecoa Ansórregui, IbanRibalta Farrés, Teresa MaríaVidal, NoemíBellosillo, BeatrizMenéndez, SilviaBarco, Sonia delGallego, OscarPineda, EstelaLópez Martos, RaquelHernández, AinhoaMesia Barroso, CarlosEsteve Codina, AnnaIglesia, Núria de laBalañá, CarmeMartínez García, MaríaNavarro, Pilar2023-07-192023-07-192023-03-082073-440936980184https://hdl.handle.net/2445/200923Glioblastoma (GBM) is the most frequent primary malignant brain tumor and has a dismal prognosis. Unfortunately, despite the recent revolution of immune checkpoint inhibitors in many solid tumors, these have not shown a benefit in overall survival in GBM patients. Therefore, new potential treatment targets as well as diagnostic, prognostic, and/or predictive biomarkers are needed to improve outcomes in this population. The beta-galactoside binding protein Galectin-1 (Gal-1) is a protein with a wide range of pro-tumor functions such as proliferation, invasion, angiogenesis, and immune suppression. Here, we evaluated Gal-1 expression by immunohistochemistry in a homogenously treated cohort of GBM (the GLIOCAT project) and correlated its expression with clinical and molecular data. We observed that Gal-1 is a negative prognostic factor in GBM. Interestingly, we observed higher levels of Gal-1 expression in the mesenchymal/classical subtypes compared to the less aggressive proneural subtype. We also observed a Gal-1 expression correlation with immune suppressive signatures of CD4 T-cells and macrophages, as well as with several GBM established biomarkers, including SHC1, PD-L1, PAX2, MEOX2, YKL-40, TCIRG1, YWHAG, OLIG2, SOX2, Ki-67, and SOX11. Moreover, Gal-1 levels were significantly lower in grade 4 IDH-1 mutant astrocytomas, which have a better prognosis. Our results confirm the role of Gal-1 as a prognostic factor and also suggest its value as an immune-suppressive biomarker in GBM.15 p.application/pdfengcc by (c) Martínez Bosch, Neus et al, 2023http://creativecommons.org/licenses/by/3.0/es/GliomaTumors cerebralsGliomasBrain tumorsinfo:eu-repo/semantics/article2023-06-21info:eu-repo/semantics/openAccess